Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications

Stock Track

04/30

3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.

The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.

Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1155891045"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155891045\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155891045?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155891045","market":"us","top_or_hot":-1,"title":"Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications","media":"Stock Track","content":"<p>3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.</p><p>The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.</p><p>Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 3SBIO Soars 6.03% Intraday as SSS68 Injection Receives IND Approval for Three Indications\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-30 11:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.</p><p>The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.</p><p>Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生製藥","start_time":0,"source_url":"","article_id":"1155891045","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155891045","pubTimestamp":1777518585,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.The movement is primarily attributed to the latest...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01530":"三生制药"},"translate_title":"个股追踪|三生制药盘中大涨6.03%SSS68注射液获三项适应症IND批件","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1},"content_text":"3SBIO's stock surged 6.03% intraday, reflecting strong investor optimism following significant regulatory progress for its pipeline assets.The movement is primarily attributed to the latest announcement from China's Center for Drug Evaluation (CDE), which granted implied approval for the clinical trial application of the Class 1 new drug SSS68 injection. This long-acting anti-APRIL/BAFF bispecific antibody is intended for the treatment of primary membranous nephropathy, lupus nephritis, and immunoglobulin A nephropathy. Notably, SSS68 is the first APRIL×BAFF bispecific antibody globally to enter the clinical stage.Additionally, investor sentiment was bolstered by the recent acceptance of the clinical trial application for SSGJ-706 injection, a next-generation tumor immunotherapy drug and one of the few PD-1/IL-15 bifunctional fusion proteins in China to reach the IND application stage.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}